Trifluridine/tipiracil with fruquintinib vs. with bevacizumab for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two combination treatments for people with advanced colorectal cancer that has stopped responding to standard therapies. You would receive either trifluridine/tipiracil plus fruquintinib or trifluridine/tipiracil plus bevacizumab, to see which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced colorectal cancer that cannot be removed by surgery and has progressed after at least two prior treatments.
- You have at least one tumor that can be measured on scans.
- You are able to swallow pills and have a life expectancy of at least 12 weeks.
- Your overall health status is good (ECOG score 0 or 1).
- You have adequate kidney, liver, and blood cell counts based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
This trial tests a new combination—fruquintinib (a targeted pill) plus TAS-102 (another chemo pill)—against a standard regimen of bevacizumab (Avastin) plus TAS-102 for people whose advanced colorectal cancer has continued to grow after multiple prior treatments.
This trial compares two drug combinations for patients whose colorectal cancer has spread and worsened after first treatment. You would receive either FOLFOX or FOLFIRI plus fruquintinib, or the same chemo plus bevacizumab, to see which works better.
This trial tests if a newer targeted drug (fruquintinib) works as well as a standard drug (bevacizumab) when combined with two chemotherapy drugs for people with advanced colorectal cancer that got worse after first treatment. It aims to find a better option for second-line treatment.
This trial tests a new schedule of two drugs—bevacizumab and trifluridine/tipiracil—given every two weeks instead of more often. The goal is to reduce severe low white blood cell counts (neutropenia) while still treating advanced colorectal cancer that has not responded to several previous treatments.
Hear when a new Refractory Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.